The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review
The Journal of Allergy and Clinical Immunology: In Practice · 2023-03 · 11 (3) · 762-772.e1
DOI: 10.1016/j.jaip.2023.01.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-03. Verfasst von Richard Beasley und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Institute of New Zealand, Wellington, New Zealand; Capital and Coast District Health Board, Wellington, New Zealand; Victoria Univer…. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Genentech, Health Research Council of New Zealand, AstraZeneca.
Abstract (Originalsprache)
The Global Initiative for Asthma recommends that low-dose inhaled corticosteroid (ICS)/formoterol be preferred to short-acting beta2-agonists as reliever therapy in adolescents and adults with asthma, across the range of asthma severity. This recommendation represents the most fundamental change in asthma management for many decades. In this commentary, we review the rationale for combination ICS/formoterol therapy, the evidence on which this recommendation has been made, the limitations in the evidence, the practical issues relevant to the implementation of ICS/formoterol reliever-based regimens in clinical practice, and the emerging evidence for the efficacy and safety of combination ICS/salbutamol reliever therapy regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Institute of New Zealand, Wellington, New Zealand; Capital and Coast District Health Board, Wellington, New Zealand; Victoria University of Wellington, Wellington, New Zealand. Electronic address: Richa…
- Medical Research Institute of New Zealand, Wellington, New Zealand.
- Medical Research Institute of New Zealand, Wellington, New Zealand; Victoria University of Wellington, Wellington, New Zealand.
Förderung
- Genentech
- Health Research Council of New Zealand
- AstraZeneca
Zitieren
APA
Beasley, R., Bruce, P., Houghton, C., & Hatter, L. (2023). The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review. The Journal of Allergy and Clinical Immunology: In Practice, 11(3), 762-772.e1. https://doi.org/10.1016/j.jaip.2023.01.002
Vancouver
Beasley R, Bruce P, Houghton C, Hatter L. The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(3):762-772.e1. doi:10.1016/j.jaip.2023.01.002
BibTeX
@article{Beasley2023,
author = {Beasley, Richard and Bruce, Pepa and Houghton, Claire and Hatter, Lee},
title = {The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2023},
volume = {11},
number = {3},
pages = {762--772.e1},
doi = {10.1016/j.jaip.2023.01.002}
}
EUVIMED